Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Masimo reports robust Q4 earnings, eyes new product launches

Masimo's Q4 2022 earnings call highlighted strong financial performance, growth projections for 2023, and a focus on innovation and regulatory advancements. While facing challenges like supply chain issues and legal disputes, the company remains optimistic about opportunities in new product launches and revenue growth drivers. Overall, Masimo is poised for continued success in the healthcare market.

Masimo reports robust Q1 earnings, navigates challenges with strategic focus

Masimo's Q1 performance reflects strong revenue growth and product innovation, underpinned by a focus on healthcare technology and wearables for chronic illness monitoring.
While facing challenges such as litigation costs and regulatory clearances, Masimo maintains its financial guidance for 2023, signaling stability and strategic resilience.
The company's emphasis on new product launches, diverse pricing strategies, and global market expansion positions it well to capitalize on opportunities in the healthcare sector.

Masimo faces revenue challenges in Q2 but eyes rebound

Masimo's Q2 performance was impacted by revenue challenges in Healthcare and non-healthcare segments, leading to a revised revenue guidance for 2023.
The company is focusing on expense control measures, new product opportunities, and pricing discipline to drive profitability and rebound in business segments.
Despite challenges, Masimo remains optimistic about market opportunities in telehealth, consumer health, and the potential for revenue growth from products like Stork.
Ongoing litigation with Apple and uncertainties in customer order patterns pose challenges, but the company is implementing strategies to address these issues.

Masimo reports solid Q3 earnings, eyes growth in consumer health

Masimo's Q3 performance showcased strong revenue but challenges in sensor utilization recovery. The company's innovative products and expansion into consumer health signal growth potential. Addressing challenges in revenue guidance and market competition will be key focus areas for future success.

Masimo reports robust Q4 earnings, legal wins and growth opportunities

Masimo's strong Q4 performance and strategic focus on healthcare and hearables/wearables growth position the company well for 2024.
Legal victories in Apple litigation and FDA clearances for innovative products underscore Masimo's commitment to innovation and protecting its intellectual property.
While facing challenges in legal proceedings and product clearances, Masimo has opportunities to drive revenue growth through product innovation and market expansion.

Masimo reports strong Q1 earnings, plans consumer business separation

Masimo's Q1 2024 Earnings Call showcased robust financial performance, strategic revenue diversification, and plans for enhancing shareholder value through potential separation of the consumer business. While facing challenges in operational transitions and financial metrics scrutiny, the company is well-positioned for growth and value creation.

Masimo reports robust Q3 performance and outlines growth opportunities

Masimo's Q3 2024 earnings call showcased strong financial performance, strategic reviews, and growth initiatives. While facing challenges in margin progression and potential disruptions, the company is poised for growth with opportunities in revenue expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

NEW YORK , June 4, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Masimo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Masimo Corporation Investors to Inquire About Securities Class Action Investigation - MASI

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that it has filed a preliminary proxy statement with the U.S. Securities and Exchange Commission in connection with its nomination of two independent candidates for election to the Masimo Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”), whi.

Politan Files Preliminary Proxy Statement

BARCELONA, Spain--(BUSINESS WIRE)--Germans Trias i Pujol Hospital in Spain is launching a breakthrough telehealth program using Masimo wearable technology and Hospital Automation™.

Germans Trias i Pujol Hospital in Spain Launches Telehealth and Remote Patient Management Program Using Masimo W1® Medical Watches and Radius VSM™ Wearable Continuous Vital Signs Monitors

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that its Board of Directors has nominated Christopher Chavez for election as a Class II Director at the Company's 2024 Annual Meeting of Stockholders. Following Rolf Classon's unexpected resignation from the Board on May 10, 2024, due to health issues, members of the Board contacted and considered several candidates with skills and experiences that would enhance the Board's slate. Mr. Chavez brings more than 30 years of lead.

Masimo Announces Nomination of Independent Candidate to the Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 1:00 p.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global technology company that develops and produces a wide array of industry-lead.

Masimo to Present in Jefferies Global Healthcare Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology provider for modern clinical trials, is partnering with industry leader Masimo (NASDAQ: MASI) to bring best-in-class medical-grade wearable devices to clinical research. Masimo's award-winning pulse oximeter technology has been widely trusted by clinicians for over 25 years to monitor more than 200 million patients each year and is now enabling more patients to participate in clinical trials without the burdens of ongoing.

Medable and Masimo Partner to Bring Best-in-Class Wearable Devices to Clinical Research, Capturing Rich Subjective and Objective Data

NEW YORK , May 28, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Masimo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Masimo Corporation Investors to Inquire About Securities Class Action Investigation - MASI

Alcon Inc. - Registered Shares

Hologic

RxSight

Veracyte

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These stocks are: ALC, RXST, HOLX, VCYT, MASI.

Buy 5 Medical Instruments Stocks to Enhance Your Portfolio

Masimo's (MASI) new product offering is expected to enable it to expand its footprint in the personalized hearables market by offering personalized listening experiences.

Masimo's (MASI) New Offering to Serve Personalized Audio Market

IRVINE, Calif. & RESTON, Va.--(BUSINESS WIRE)--Masimo is the first pulse oximetry manufacturer recognized by Practice Greenhealth as Greenhealth Approved, for Masimo RD pulse oximetry sensors.

Masimo Receives Sustainability Seal of Approval from Practice Greenhealth

NEW YORK , May 18, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Masimo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Masimo Corporation Investors to Inquire About Securities Class Action Investigation - MASI

IRVINE, Calif.--(BUSINESS WIRE)--Denon PerL™ and PerL Pro™ True Wireless earbuds - the epitome of personalized audio listening - are now available in white.

Masimo and Denon Introduce White PerL™ and PerL Pro™ Earbuds, Redefining Style and Customization in Personalized Audio

NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI). The investigation concerns whether Masimo and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On May 7, 2024, Masimo disclosed that it had received a subpoena from the Department of Justice in February “see.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Masimo Corporation (MASI)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Masimo investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Masimo Corporation (MASI) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI) investors concerning the Company's possible violations of federal securities laws. On May 7, 2024, Masimo disclosed that it had received a subpoena from the Department of Justice (“DOJ”) in February “seeking documents and information related to the Company's Rad-G and Rad-97 products, including information relating to complaints sur.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Masimo Corporation (MASI) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On May 7, 2024, Masimo disclosed that it had received a subpoena from the Department of Justice (“DOJ”) in February “seeking documents and information related to the Company's.

The Law Offices of Frank R. Cruz Announces Investigation of Masimo Corporation (MASI) on Behalf of Investors

NEW YORK , May 11, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Masimo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Masimo Corporation Investors to Inquire About Securities Class Action Investigation - MASI

Masimo offered to settle with a dissident director who is planning a second proxy fight.

Masimo seeks to stave off proxy fight with Politan, makes settlement offer

Masimo said on Thursday that it is prepared to appoint Politan Capital Management's nominee William Jellison as a director on its board, if the activist investor withdraws its other nominee and drops its proxy contest.

Masimo says prepared to provide one board seat to activist Politan

Masimo activist Quentin Koffey says he'll pursue litigation if the health-tech company doesn't provide information on a proposed spinout of a business unit.

Masimo activist director Koffey demands ‘basic' information on company's proposed spinoff

Masimo's (MASI) Q1 healthcare revenues reflect strong sensor orders, which were completely offset by lower capital equipment purchases. Sensor production in Malaysia is likely to improve Healthcare gross margin.

Masimo (MASI) Q1 Earnings Beat Estimates, '24 EPS View Up

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the BofA Securities Health Care Conference on Wednesday, May 15, 2024 at 4:20 p.m. Pacific Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global technology company that develops and produces a wide array of industry-lead.

Masimo to Present in BofA Securities Health Care Conference

Masimo Corporation (NASDAQ:MASI ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Eli Kammerman - Vice President of Business Development & Investor Relations Joe Kiani - Chairman & Chief Executive Officer Micah Young - Executive Vice President & Chief Financial Officer Conference Call Participants Rick Wise - Stifel Marie Thibault - BTIG Vik Chopra - Wells Fargo Mike Polark - Wolfe Research Operator Good afternoon ladies and gentlemen and welcome to Masimo's First Quarter 2024 Earnings Conference Call. The company's press release is available at www.masimo.com.

Masimo Corporation (MASI) Q1 2024 Earnings Call Transcript

The headline numbers for Masimo (MASI) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Masimo (MASI) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Results: Consolidated revenue was $492.8 million, comprised of healthcare revenue of $339.6 million and non-healthcare revenue of $153.2 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 50,400. Consolidated GAAP operating income was $34.0 million. Consolida.

News for Masimo Stock (MASI)